BLACKROCK Municipal Income TRUST V.BFK.P

Primary Symbol: BFK

BlackRock Municipal Income Trust (the Fund) is a diversified closed-end management investment company. The Fund's investment objective is to provide current income exempt from federal income taxes. Under normal market conditions, the Fund invests at least 80% of its managed assets in investments the income from which is exempt from federal income tax (except that the interest may be subject to the alternative minimum tax). The Fund may invest directly in securities or synthetically through the use of derivatives. The Fund's investment policies provide that it invests at least 80% of its total assets in investment grade quality municipal obligations issued by or on behalf of states, territories and possessions of the United States and their political subdivisions, agencies or instrumentalities, each of which pays interest that, in the opinion of bond counsel to the issuer, is excludable from gross income for federal income tax purposes. Its investment adviser is BlackRock Advisors, LLC.

NYSE:BFK - Post by User

BLACKROCK Municipal Income TRUST

Bullboard Posts

Comment by Analystguyon Aug 27, 2019 7:16pm

140 Views

Post# 30072588

RE:RE:Health Canada Cannabis Sales Figures - HEXO Q4 Projections

Sort of inline with what I estimate. I note that headcount is above 1300 and the production run rate over the past 3 quarters is about 12 kg per employee although last quarter I read that it had over 19 thousand kg in production.

HEXO
Profit and Loss (P&L) Statement
CDN $ (thousands)	2019
	Q1	Q2	Q3	Q4
Parameters
Excise Tax Rate % =		0.176	0.176	0.176
kg Produced	3,552	4,932	9,804	15,500
Inventory (kg)	2,442	2,526	7,274	11,172
Headcount	283	374	822	1,300
Adult Use
Dried gram equivalents sold (kg)	952.2	2,537.7	2,759.0	5,000.0
Gross revenue per gram equivalent	$ 5.45	$ 5.83	$ 5.29	$ 5.23
Net revenue per gram equivalent	$ 4.44	$ 4.81	$ 4.30	$ 4.25

Medical Use
Dried gram equivalents sold (kg)	157.5	151.5	145.0	150.0
Gross revenue per gram equivalent	$ 9.12	$ 9.15	$ 9.11	$ 9.05
Net revenue per gram equivalent		$ 7.73	$ 7.52	$ 7.35


Adult Use	-	-	-	-
Gross Revenue	5,194.0	14,792.0	14,607.0	26,166.7
Excise Tax	(970.0)	(2,587.0)	(2,741.0)	(4,605.3)
Adult Use Net Revenue	4,224.0	12,205.0	11,866.0	21,561.3
	-	-	-	-
Medical Use
Gross Revenue	1,436.0	1,387.0	1,323.0	1,357.5
Excise Tax	(44.0)	(216.0)	(233.0)	(238.9)
Medical Use Net Revenue	1,392.0	1,171.0	1,090.0	1,118.6

Ancillary Revenue	47.0	62.0	61.0	65.0
Total Net Revenue	5,663.0	13,438.0	13,017.0	22,744.9

Cost of Goods Sold	2,831.0	6,499.0	6,577.0	11,642.3
Gross margin before fair value adjustments	2,832.0	6,939.0	6,440.0	11,102.7
gross margin %	0.50	0.52	0.49	0.49

Loss (gain) in fair value inventory sold	717.5	3,690.0	4,665.0	9,206.0
Loss (gain) on fair value biological assets	(5,123.0)	(8,354.0)	(20,057.0)	(30,805.2)
Gross Margin	7,237.5	11,603.0	21,832.0	32,701.8